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It is well known that cardiovascular diseases (CVD) are a growing cause of mortality and morbidity in 
low-and middle-income countries (LMIC). While hypertension (HTN), a leading risk factor for CVD, 
can be easily managed with widely available medicines, there is a huge gap in treatment for HTN in 
many LMIC. One such country is Kyrgyzstan, where HTN is a major public health concern and 
adherence to medication is low. The reasons for low adherence in Kyrgyzstan are not well understood, 
but some evidence suggests that HTN medicines may be unaffordable for low-income families, 
resulting in inequitable access to HTN treatment.  With data from the 2010 Kyrgyzstan Integrated 
Household Survey, we estimate the prevalence and factors associated with adherence to HTN 
medication in Kyrgyzstan. We then investigate the hypothesis that affordability may be an important 
factor in adherence to HTN medication. Using the novel coarsened exact matching approach, we 
estimate the economic burden faced by households with at least one member with elevated blood 
pressure (EBP) in Kyrgyzstan and their risk of catastrophic spending on health care.  We find that 
EBP households have significantly higher total expenditure on health, as well as on medicines, and 
are more likely to experience catastrophic health spending, suggesting that out-of-pocket expenditure 
for EBP may be prohibitively expensive for the poorest in Kyrgyzstan. Our findings also reveal a high 
prevalence of self-medication (i.e. purchasing and using medication without a doctor’s prescription), 
and increased expenditure due to self-medication, among those with EBP.  Our research suggests that 
affordability of HTN medicines may be an important factor in low adherence to treatment in 
Kyrgyzstan. Low affordability may be due partly to prescription of medicines that are not 
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reimbursable under the national drug benefit plan, but more research is needed to identify solutions to 
the affordability problem. 
Introduction 
The countries of the former Soviet Union (fSU) have the highest burden of ischemic heart disease 
(IHD) of any region in the world (1) yet their health systems have struggled to respond. This is 
especially apparent with hypertension (HTN), a leading risk factor for IHD, which often goes 
undetected and untreated in this region. (2) In Kyrgyzstan, a low-income former Soviet country, HTN 
is a particularly pressing public health concern. (3) The estimated prevalence of raised blood pressure 
(systolic blood pressure >140 mmHg or diastolic blood pressure > 90mmHg or on treatment, based on 
a 2007 household survey), is just over 30%. (3) The most recent Global Burden of Disease Study, 
although based on modelled data, ranks HTN as the second-leading cause of disability-adjusted life 
years in the country, after dietary risk factors. (4)  
The Kyrgyz government has responded by making HTN one of six priority conditions, which since 
1996 have been the focus of a package of reforms that include removing official fees for primary care 
visits for all Kyrgyz citizens, developing and distributing HTN treatment guidelines, training health 
professionals in HTN management, and including HTN medicines in the subsidized Additional Drug 
Benefit plan, a national scheme for central purchasing and distribution of generic medicines to 
pharmacies. (3)  
Despite these efforts, changing how people respond to HTN remains a challenge.  The above-
mentioned 2007 study revealed that only 27% of those with elevated blood pressure (EBP) were 
aware of their condition and even fewer (17% of those with EBP) were following a daily regimen of 
medical treatment. (3) A separate study in 2010 suggested that only 30.7% of individuals who 
reported having been diagnosed with HTN by a doctor were taking medication daily. (2) The authors 
of the 2007 study suggested that low awareness of EBP is likely a result of low utilization of primary 
health care, especially among men, which results in a large share of asymptomatic EBP going 
undiagnosed, leading them to propose two hypotheses to explain low adherence to medications. (4) 
First, medical practice in Kyrgyzstan may not be fully in line with guidelines, despite training efforts, 
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and patient engagement is weak and ineffective. Second, despite wide availability of generic 
medicines in the country, affordability may be a concern due to a preference among physicians and 
patients for branded or more costly generic drugs. From a policy perspective, it is important to 
understand whether inadequate medical practice or affordability drives poor adherence because the 
two factors require different policy responses. The former calls for further training, stronger 
monitoring efforts, reform of financial incentives, and effective mechanisms for patient 
empowerment. In contrast, the latter calls for measures to encourage use of generic drugs, market 
interventions and greater subsidies.   
There is evidence that lends support to the affordability hypothesis as a key driver low adherence.  
Research from other countries in the region has identified out-of-pocket costs as a significant barrier 
to accessing medicines for chronic conditions. (5) In Kyrgyzstan specifically, data from repeated 
cross-sectional surveys between 2001 and 2007 suggest that, while health system financing reforms 
have succeeded in reducing out-of-pocket (OOP) payments for inpatient care and improving access to 
outpatient care, the financial burden faced by the poor when seeking care remains significant, 
especially for drugs. (6) Further research supported by the World Health Organization (WHO) on 
drugs for hypertension in 2013 found that a month’s supply of hydrochlorothiazide (a diuretic) in 
Kyrgyzstan cost the equivalent of 8.3 days wages for a worker on minimum wage (28 Som or 
approximately $0.60 USD per day) and 0.69 days wages for  a worker making the average wage. (7) 
For statins (cholesterol-lowering drugs) the situation is worse, with a month's supply of atorovostatin 
costing 31 days wages for a minimum-wage worker and 2.58 days wages for a worker on the average 
wage. In contrast, in the survey on which the above-mentioned 2007 study was based, only 10% of 
those not taking prescribed medication in the last 24 hours cited affordability as the reason. (3) 
However, this could be an artefact of the wording and sequencing of the question, with its focus on 
the last 24 hours only, which may fail to capture the overall financial burden of out-of-pocket drug 
costs and its impact on adherence. In sum, empirical evidence thus far is conflicting and calls for 
further exploration of whether hypertension medicines are affordable in Kyrgyzstan and whether 
affordability is related to adherence.   
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In our study, we explore the affordability hypothesis in more depth.  Specifically, we seek to explore 
i) the determinants of adherence to hypertension medicines in Kyrgyzstan, in particular household 
economic status, and ii) what the economic impact of drug expenditure is on households with EBP at 
different socio-economic levels. Our exploration of the affordability of medicines for hypertension 
and its role in adherence is important for the current policy discourse in Kyrgyzstan but will also be 
useful for other low and middle income countries where significant primary care and health financing 
reforms have been implemented in line with international standards, but where HTN outcomes have 
been slow to change.    
Methods 
We used data from the Kyrgyzstan Integrated Household Survey (KIHS) 2010. The KIHS combines a 
diary method and quarterly face-to-face interviews to record household consumption. Every 3 to 4 
years, a health module is added to the first quarter interviews of the KIHS to record health care 
utilization and related household expenditures. Since 2007, the health module has included a small 
section on hypertension measurement and cardiovascular disease risk factors. The KIHS is based on a 
random sample of the population stratified by oblast (region) and urban/rural place of residence. The 
samples are representative at the national and regional levels. The survey over-samples some remote 
populations in rural areas to ensure power for poverty estimates so sampling weights are used in all 
analyses. The KIHS 2010 included 4,681 households consisting of 19,091 individuals. The total 
population of Kyrgyzstan is estimated at 5.548 million, with a median age of 25, a life expectancy of 
69 years and a healthy life expectancy of 61 years. The leading cause of death in Kyrgyzstan is 
ischemic heart disease (31.7%), followed by stroke (13.8%). (8) 
In KIHS 2010, each respondent over 18 years had their blood pressure measured using an electronic 
sphygmomanometer (Model:A&D UA-767 Plus). Blood pressure was measured once, while the 
participant was seated. Because the standard criteria for diagnosing HTN in surveys requires repeated 
blood pressure measurements over the course of several days, here we use the term EBP. (9) For the 
purpose of this analysis, EBP was defined as systolic blood pressure greater than or equal to 140 
mmHg, or diastolic blood pressure greater than or equal to 90 mmHg, or having taken medicine for 
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hypertension in the last 24 hours. Blood pressure measurements were recorded for roughly 89% of 
eligible participants (i.e. 18 years of age or older), resulting in an 11% non-response rate for this 
measure. As in the 2007 survey, non-response was non-random; missing values differed by age and 
gender with a greater than average share of missing values among younger people and among men. 
Consequently, imputation was used, following the approach taken in the 2007 study (3), with values 
estimated from means of region (n=8), age category (18-29, 30-39, 40-49, 50-59, 60-69, 70+) and 
gender specific strata. This imputation technique ensured that there were values for systolic and 
diastolic blood pressure for everyone aged 18 years or older. 
Adherence was defined as reporting having taken anti-hypertensives in the last 24 hours (among those 
who were aware of their condition due to doctor diagnosis). Logistic regression was used to estimate 
the impact of socioeconomic status on adherence, controlling for age, gender, oblast, urban/rural place 
of residence, marital status and insurance status (i.e. whether or not the individual was enrolled in the 
mandatory insurance program; 97% of survey respondents were enrolled). Socioeconomic status was 
defined by each household’s monthly per capita consumption, divided into terciles. 
Investigating the economic burden of anti-hypertensives on households in Kyrgyzstan empirically is 
challenging. While the KIHS provides information about blood pressure and general out-of-pocket 
medicine expenses, it is not possible to separate out-of-pocket payments for anti-hypertension 
medicines from other medicines. To overcome this challenge, we use coarsened exact matching 
(CEM) to match households with at least one member with EBP with households with no EBP that 
are similar in other characteristics that might affect drug expenditure. This matching allows us to 
suggest that differences in out-of-pocket health expenditure and risk of catastrophic health spending 
(> 40% of effective income (income after food spending) spent on health (10) are attributable to 
having a household member with EBP. The CEM method has been described in detail elsewhere, (11, 
12) and used in recent research to investigate the impact of angina on household health expenditure. 
(5) Briefly, CEM attempts to control for the potential confounding of ‘pre-treatment’ covariates on the 
outcome of interest, by matching ‘treatment’ cases with ‘non-treatment’ cases that are approximately 
similar with regard to those covariates. In our case, ‘treatment’ cases are households containing at 
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least one member with elevated blood pressure (EBP) and ‘non-treatment’ controls are households 
where no-one has EBP. Relative to beginning analysis with a parametric regression model, 'pre-
processing' the data using matching reduces model dependence and statistical bias. (11) Matching 
methods enable us to make the treatment group as similar as possible to the control group making the 
treatment variable closer to being independent of the background covariates.(13) CEM has an 
advantage over other methods of matching observational data such as propensity-score matching 
(PSM) and exact matching (EM) in that it doesn’t require that the matched observations are balanced 
in terms of pre-treatment covariates as does PSM, nor does it require matched observations to be 
precisely similar in terms of these covariates as in EM.(5, 11, 14) 
We used CEM to account for potential confounding by the following pre-treatment household 
characteristics: i) household size ii) socio-economic status of the household) iii) proportion of females 
in the household (to account for the possibility of higher health expenditure associated with older 
men) iv) proportion of people over the age of 60 in the household and v) proportion of children under 
the age of 2 in the household. After matching, we used linear regression to analyse the difference in 
mean total health care expenditure, mean total expenditure on medicines and mean total expenditure 
on self-medication associated with having at least one member with EBP in the household. We then 
used logistic regression to analyse the odds of catastrophic spending among EBP households, 
compared with non-EBP households. 
Results 
Descriptive results: sample characteristics, hypertension prevalence, awareness and adherence  
The characteristics of our sample are described in Table 1. The sample was almost equally divided by 
gender, urban/rural place of residence and oblast. Those aged less than 18 years were not included in 
subsequent analyses of EBP. 
Table 2 shows the estimated prevalence of EBP, the percentage of individuals who are aware of their 
condition, and the percentage of those who are aware that are adhering to hypertension medication. 
The crude prevalence of EBP for the whole population is 23.7%. EBP prevalence is slightly higher 
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among women compared to men, and as expected, in older age groups. Less than half (48.5%) of the 
total population of individuals who are aware of having hypertension are adhering to medical 
treatment, and adherence is lowest in younger age groups, especially among young men. The 
percentage of individuals with EBP who are aware their condition was higher in the richest income 
tercile (40.2%, 95% CI: 32.7,47.5) compared to the middle (31.1%, 95% CI: 25.2, 37.0) and poorest 
(21.4, 95%CI: 16.7, 26.0) groups. 
Determinants of adherence 
The results of our logistic model of adherence (among those who are aware of their HTN status) are 
shown in Table 3. Adjusting for possible confounders, odds of adherence to medical treatment 
increased significantly as socio-economic status increased. Those in the richest income tercile were 
2.28 times more likely to adhere to medical treatment compared to those in the poorest tercile. There 
was no significant association with age, gender, or urban/rural dwelling. However, those who were 
divorced were 60% as likely to adhere to medication and there were significantly lower odds of 
adherence in four oblasts: Naryn (OR=0.30), Batken (OR=0.18), Talas (OR=0.16) and Chui 
(OR=0.27).  
Economic burden of hypertension treatment 
Our weighted, unmatched analysis of expenditure among households (who reported expenditure >0) 
with and without a member with EBP suggests that households with at least one member with EBP 
experience greater out of pocket expenditures for prescribed outpatient medicines than households 
without EBP.  (Table 4)  Expenditure on anti-hypertensives, our primary interest in this study, would 
be counted in the prescribed outpatient drug category.  (Table 4, Column 1)  The difference in mean 
per capita spending on outpatient medicines between these groups is 585.14 KGS (12.7 US$).  
Spending varies significantly by socio-economic status. Among the poorest third of the population, 
mean per capita spending on outpatient medicines among households with EBP amounts to 1376.65 
KGS (29.9 US$) or 31 % of annual per capita effective income in that group.  As expected the middle 
and richest thirds spend more, 1549.86 KGS (33.7 US$) and 4024.75 KGS (87.5 US$) respectively, 
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but this amounts to a lower percentage of their annual per capita effective income (17% and 19% 
respectively). 
Because expenditure on self-medication was higher than expected, we examined its prevalence among 
those with EBP and found that, on average 19% of males with EBP (9% in the youngest age category 
and 45% in the oldest) reported self-medicating. For females this figure was 36% (10% in the 
youngest category and 46% in the oldest). The data do not allow us to know for what conditions 
individuals are self-medicating.  
After matching on the proportions of people in the household over the age of 60, under the age of 2, 
male, household size, urban vs. rural residence and consumption tercile, EBP households were found 
to be spending 335.57 KGS more in total on health expenditure, almost 400 KGS more per capita on 
drugs and 208.69 KGS more on self-medication. The 400 KGS difference in per capita spending on 
drugs is equivalent to roughly 3% of annual per capita household non-food consumption among all 
households (12 022.45, S.E. = 338.06 KGS). The odds of catastrophic health spending among EBP 
households are 1.48 times higher than that of non-EBP households. (Table 5) 
Discussion 
To the best of our knowledge, this is the first study that analyses the role of various socio-
demographic and socio-economic factors, in explaining low levels of adherence to anti-hypertensive 
drug regimens in Kyrgyzstan. The crude prevalence of EBP we found using 2010 KIHS data is 
slightly lower than that of the 2007 study, despite using the same definition. This difference may be 
due to an artefact of the data arising from the collection process (e.g. more highly skilled data 
collectors or less mis-reporting of taking drugs for EBP). Alternatively, it may represent some 
improvements in treating HTN in Kyrgyzstan since 2007 due to the development of initiatives such as 
quality improvement training for physicians with respect to identification and treatment of HTN, and 
HTN clubs for patients that provide education and support of lifestyle improvements. (15) 
Our findings confirm the low rate of adherence reported in 2007, as less than half of the total 
population of individuals in our study who are aware of having hypertension are adhering to medical 
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treatment. This may be due to inaccurate prescription advice given by physicians, a poor 
understanding of the importance of daily adherence on the part of patients or a preference for brand-
name drugs that are unaffordable for daily use by poorer patients. These are issues that should be 
further explored in qualitative studies. Our results provide new evidence that poorer individuals are 
indeed less likely to adhere to HTN medication regimens. Using a novel approach to match on 
potential confounders, we further found that households with at least one member with EBP had 
significantly higher total expenditure on health, as well as on medicines, and were more likely to 
experience catastrophic health spending, suggesting that out-of-pocket expenditure for EBP may be 
prohibitively expensive for those in the poorest income groups in Kyrgyzstan.  
Our findings also showed a high prevalence of self-medication (i.e. purchasing and using medication 
without a doctor’s prescription) among individuals with EBP Self-medication is a common practice in 
countries of the former Soviet Union (16) and can include treating one’s illnesses with herbs, alcohol 
and traditional medicines. (17) In a recent study in 8 fSU countries, the most frequent reason cited for 
not seeking health care when doing so would be justified was the cost of treatment (including drugs), 
followed by the choice to self-medicate. (16) In a study using the same survey, 25% of Kyrgyz 
respondents reported that they would use a folk healer if they had one of ten common conditions, by 
far the highest frequency in the 8 countries. (18) While self-medication may be a cultural 
phenomenon, in cases where it involves the use of cheaper drugs or other remedies, it may also imply 
unaffordability of doctor-prescribed medical treatment, suggesting that the influence of drug costs on 
adherence may be even greater than is apparent from individuals’ reports of reasons for non-
adherence. However, it is also possible that some cases involve attempts to manage real or perceived 
side effects of anti-hypertensive medication. While our findings suggest an increase in expenditure 
among EBP households due to self-medication, this difference was not large enough to conclude that 
self-medication is a major driver of expenditure or adherence to prescribed treatment.  
The Kyrgyz government has acknowledged the importance of ensuring access to outpatient 
pharmaceuticals in order to strengthen primary care. As part of a programme of health care reform, 
mandatory health insurance was introduced in 1996 and included among its benefits the Additional 
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Drug Package (ADP) that subsidized the cost of essential outpatient medicines.  (19) This includes 
four classes of cardiovascular medicines: ACE inhibitors (enalapril and lisinopril); diuretics 
(hydrochlorothiazide, frusemide); calcium channel blockers (amlodipine, verapamil and nifedipine); 
and beta blockers (bisoprolol and atenolol). These medicines are sold at prices comparable to 
international guide prices. Subsequent assessments of the ADP have found that it has been crucial in 
ensuring popular support for the reform programme and for increasing demand for primary care 
services and access to essential medicines in remote areas. (20) It has been shown to have improved 
access to medicines, increased generic and rational prescribing practices and led to a partial 
introduction of prescription-based sales of medicines. (19) However, some other important 
cardiovascular medicines are not included in the ADP and, as noted above, statins are much more 
expensive, typically twelve fold higher or more, than the international guide price.(21) 
Nevertheless, affordability of medicines remains a problem and may be partly due to irrational 
prescribing practices as well as high levels of self-medication. (22) There is a lack of popular 
understanding of rational drug use in Kyrgyzstan, which is problematic where almost all medicines 
can be purchased over-the-counter without prescription, and there is a low adherence to clinical 
protocols among medical professionals. (22) Both doctors and patients have been reluctant to embrace 
generic substitution as almost 60% of doctors believe that the effectiveness of cheaper generics under 
International Nonproprietary Name (INN) is much lower in comparison with much more expensive 
branded drugs (23). (Research in 2008 by the WHO into the quality of public-sector drugs in 
Kyrgyzstan suggests that this belief is not wholly unfounded, as the quality of 62% of anti-
hypertensives in the country could not be proven. (24)) Only 30% of funds allocated for the 
reimbursement of patients through the ADP are for generic unbranded medicines while 70% goes to 
more expensive generics from certain popular manufacturers. (22) Moreover, a recent assessment by 
the WHO in 2013 reported that funds  allocated to the ADP are underused, which suggests that 
doctors are prescribing medicines that are not included on the reimbursement list. (7) In addition, 
internal migration, which has been considerable but extremely complex,(25) affects uptake of the 
ADP because people often do not enroll with a new primary care facility at their new place of 
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residence and without registration, they do not have access to ADP benefits.  (20) It should also be 
noted that the ADP does not necessarily cover the full cost of the prescribed medicine but rather pays 
according to a reference price, which may be less than the price for which the pharmacist sells it. (19) 
Our findings highlight the fact that despite the positive steps taken in Kyrgyzstan to ensure free 
primary health care and to subsidize medicines for HTN, inequity in health care access for HTN may 
still exist, as demonstrated by lower adherence to medicines and greater financial burden suffered by 
poorer income groups. The most recent health reform in Kyrgyzstan - Den sooluk (2012-16) - is a 
continuation of the previous Manas Taalimi reform programme (2006-2011) with continued aims of 
improving the quality and accessibility of care and the health of the population. (26) The Den Sooluk 
focuses especially on selected priority diseases including CVD, as the main cause of mortality. Given 
the continued focus on CVD through the Den Sooluk, levels of awareness and adherence to 
medication for CVD conditions (including HTN) could be different now than they were in 2010, but 
the impact of this programme has yet to be evaluated. Updated KIHS data are scheduled to become 
available next year - analyses of these data that can follow up on this paper, identifying any changes 
in awareness and adherence, would provide valuable insights into the effectiveness of these reforms.  
 
Limitations 
As indicated in our Methods section, we relied on a single measurement of blood pressure while 
seated in order to define EBP. Using only one measurement may result in either under- or over-
estimate HTN; however, in our case more than one measurement was not feasible and the definition 
of EBP used in our study is consistent with that used in international literature on HTN prevalence. 
(9) Our definition of adherence may also introduce some limitations, as it is possible that individuals 
who report taking medication in the preceding 24 hours are not necessarily taking medication every 
day. In this case we would be over-estimating prevalence of adherence in this population. Our 
analysis is also limited by the fact that we could not estimate the effect of education on adherence, as 
the KIHS 2010 did not include information on education. Education is likely associated with 
awareness of HTN and adherence to treatment, and also likely to be correlated with income. However, 
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the KIHS 2010 was primarily focused on level of health care utilization rather than determinants, and 
only a small number of demographic variables was included. 
As also discussed above, it is not possible in the KIHS to separate out expenditure specifically related 
to HTN. Reported spending on outpatient medicines could also include medicines for other non-HTN-
related conditions (e.g. common cold remedies, allergy medicines, etc). While it is likely that 
expenses for non-HTN-related conditions are evenly distributed between households with and without 
EBP, our matching analysis allowed us to more accurately attribute any differences in expenditure to 
HTN-related treatment. However, there are a number of health conditions that are more likely in 
persons with hypertension, such as cardiovascular disease and stroke. Thus, our approach may over-
estimate the burden specifically attributable to hypertension. The greater financial burden of EBP 
households in fact is likely to be due to a range of cardiovascular conditions. Nevertheless, our 
approach shows that having hypertension is a good and easily observable marker to identify 
households more likely to experience catastrophic health expenditures. This can perhaps be used for 
targeting of health benefits, for example subsidies for medicines.  
Conclusion 
Ensuring the affordability of medicines in Kyrgyzstan is an important policy priority, but a broad and 
complex set of measures is required to address it.  The reimbursement of HTN treatments through the 
ADP is important, but measures to support rational prescribing and consumption patterns are also 
necessary, and until the mistrust of cheap generics, and the lack of strict regulation of the quality of 
these medicines, is overcome, the affordability of medicines for long-term conditions will remain a 
key concern for households. 
This paper contributes to our understanding of how self-medicating is an important aspect of 
affordability and needs to be routinely taken into account in countries where most drugs can be 
purchased over the counter.  It also points to a need for more research on trust, health beliefs and the 
role of advertising in how patients make decisions about the consumption of medicines.   
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